Wall Street analysts expect Johnson & Johnson (NYSE:JNJ) to report sales of $20.21 billion for the current quarter, according to Zacks. Five analysts have issued estimates for Johnson & Johnson’s earnings, with estimates ranging from $20.03 billion to $20.62 billion. Johnson & Johnson posted sales of $18.11 billion during the same quarter last year, which suggests a positive year over year growth rate of 11.6%. The company is expected to announce its next earnings report before the market opens on Tuesday, January 23rd.
On average, analysts expect that Johnson & Johnson will report full year sales of $20.21 billion for the current fiscal year, with estimates ranging from $76.21 billion to $80.09 billion. For the next fiscal year, analysts anticipate that the company will post sales of $81.54 billion per share, with estimates ranging from $80.72 billion to $82.66 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the previous year, the business earned $1.68 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis.
A number of research firms have recently issued reports on JNJ. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a report on Monday, September 18th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a report on Wednesday, October 18th. Citigroup boosted their target price on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Jefferies Group raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the company from $145.00 to $157.00 in a report on Wednesday, October 11th. Finally, Argus boosted their target price on Johnson & Johnson from $145.00 to $165.00 and gave the company a “positive” rating in a report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $145.52.
Johnson & Johnson (NYSE:JNJ) traded up $1.16 during trading hours on Tuesday, hitting $141.71. The stock had a trading volume of 5,900,718 shares, compared to its average volume of 5,570,000. The firm has a market capitalization of $380,710.00, a price-to-earnings ratio of 24.60, a P/E/G ratio of 2.65 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $144.35.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.37%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
A number of hedge funds have recently made changes to their positions in JNJ. Harding Loevner LP acquired a new stake in Johnson & Johnson in the second quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its holdings in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson in the second quarter valued at $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Johnson & Johnson in the second quarter valued at $177,000. 65.70% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Analysts Expect Johnson & Johnson (JNJ) Will Post Quarterly Sales of $20.21 Billion” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://ledgergazette.com/2018/01/13/analysts-expect-johnson-johnson-jnj-will-post-quarterly-sales-of-20-21-billion.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.